Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

PD-L1 checkpoint blockade delivered by retroviral replicating vector confers anti-tumor efficacy in murine tumor models.

Mitchell LA, Yagiz K, Hofacre A, Viaud S, Munday AW, Espinoza FL, Mendoza D, Rodriguez-Aguirre ME, Bergqvist S, Haghighi A, Miner MV, Accomando WP, Burrascano C, Gammon D, Gruber HE, Jolly DJ, Lin AH.

Oncotarget. 2019 Mar 19;10(23):2252-2269. doi: 10.18632/oncotarget.26785. eCollection 2019 Mar 19.

2.

Efficient Therapeutic Protein Expression Using Retroviral Replicating Vector with 2A Peptide in Cancer Models.

Hofacre A, Yagiz K, Mendoza D, Lopez Espinoza F, Munday AW, Burrascano C, Singer O, Gruber HE, Jolly DJ, Lin AH.

Hum Gene Ther. 2018 Apr;29(4):437-451. doi: 10.1089/hum.2017.205. Epub 2018 Apr 2.

3.

Extensive Replication of a Retroviral Replicating Vector Can Expand the A Bulge in the Encephalomyocarditis Virus Internal Ribosome Entry Site and Change Translation Efficiency of the Downstream Transgene.

Lin AH, Liu Y, Burrascano C, Cunanan K, Logg CR, Robbins JM, Kasahara N, Gruber H, Ibañez C, Jolly DJ.

Hum Gene Ther Methods. 2016 Apr;27(2):59-70. doi: 10.1089/hgtb.2015.131. Epub 2016 Feb 26.

4.

Retroviral Replicating Vectors Deliver Cytosine Deaminase Leading to Targeted 5-Fluorouracil-Mediated Cytotoxicity in Multiple Human Cancer Types.

Twitty CG, Diago OR, Hogan DJ, Burrascano C, Ibanez CE, Jolly DJ, Ostertag D.

Hum Gene Ther Methods. 2016 Feb;27(1):17-31. doi: 10.1089/hgtb.2015.106. Epub 2015 Dec 1.

5.

Blockade of type I interferon (IFN) production by retroviral replicating vectors and reduced tumor cell responses to IFN likely contribute to tumor selectivity.

Lin AH, Burrascano C, Pettersson PL, Ibañez CE, Gruber HE, Jolly DJ.

J Virol. 2014 Sep 1;88(17):10066-77. doi: 10.1128/JVI.02300-13. Epub 2014 Jun 25.

6.

Design and selection of Toca 511 for clinical use: modified retroviral replicating vector with improved stability and gene expression.

Perez OD, Logg CR, Hiraoka K, Diago O, Burnett R, Inagaki A, Jolson D, Amundson K, Buckley T, Lohse D, Lin A, Burrascano C, Ibanez C, Kasahara N, Gruber HE, Jolly DJ.

Mol Ther. 2012 Sep;20(9):1689-98. doi: 10.1038/mt.2012.83. Epub 2012 May 1. Erratum in: Mol Ther. 2013 Feb;21(2):494.

7.

1,3-Bis-[7-(3-amino-2,4,6-triiodophenyl)-heptanoyl]-2-oleoyl glycerol.

Burrascano C, Dow WC, Chopra A.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2007 Aug 29 [updated 2007 Dec 18].

8.

Imaging efficacy of a hepatocyte-selective polyiodinated triglyceride (DHOG-LE) for contrast-enhanced CT.

Doerr-Stevens JK, Bakan DA, Lee FT Jr, Chosy SG, Markhardt BK, Bonneville AK, Burrascano C, Delaney C, Longino MA, Greener Y, Weichert JP.

Acad Radiol. 2002 May;9 Suppl 1:S200-4. No abstract available.

PMID:
12019869
9.

Physical and biochemical stability of Optison, an injectable ultrasound contrast agent.

Podell S, Burrascano C, Gaal M, Golec B, Maniquis J, Mehlhaff P.

Biotechnol Appl Biochem. 1999 Dec;30 ( Pt 3):213-23.

PMID:
10574690
10.

The Chlamydomonas zygospore: mutant strains of Chlamydomonas monoica blocked in zygospore morphogenesis comprise 46 complementation groups.

VanWinkle-Swift K, Baron K, McNamara A, Minke P, Burrascano C, Maddock J.

Genetics. 1998 Jan;148(1):131-7.

11.

Supplemental Content

Loading ...
Support Center